Holen Sie sich die Stockscreener-App
89.77
2.23%
-2.05
Handel nachbörslich:
89.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$91.82
Offen:
$90.88
24-Stunden-Volumen:
2.16M
Relative Volume:
2.03
Marktkapitalisierung:
$11.73B
Einnahmen:
$2.72B
Nettoeinkommen (Verlust:
$254.30M
KGV:
43.44
EPS:
2.0665
Netto-Cashflow:
$564.37M
1W Leistung:
-8.04%
1M Leistung:
-16.33%
6M Leistung:
-24.72%
1J Leistung:
-11.00%
1-Tages-Spanne:
$88.53
$91.23
1-Wochen-Bereich:
$88.53
$97.98
52-Wochen-Spanne:
$88.53
$129.50
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Vergleichen Sie RVTY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
89.77 | 11.73B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
421.85 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
184.96 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
406.65 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
100.26 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.22 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus
Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com
Revvity price target lowered to $120 from $140 at Bernstein - TipRanks
Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Green Market Report
Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus
BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus
KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener
Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus
Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener
KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia
KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating - MarketScreener
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price - simplywall.st
Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery - Technology Networks
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Technology Networks
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan
FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo
Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus
FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa
What's Going On With Revvity Stock Today? - Benzinga
(RVTY) Investment Analysis - news.stocktradersdaily.com
Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener
FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing
Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha
Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - marketscreener.com
FDA greenlights Revvity’s TB diagnostic platform - Investing.com India
Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener
Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan
Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Is Revvity Stock Underperforming the Nasdaq? - MSN
High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Revvity Stock Underperforming The Nasdaq? - Barchart.com
Is Revvity Gaining or Losing Market Support? - Benzinga
Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks
Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN
The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace
Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener
Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan
May 16th Options Now Available For Revvity (RVTY) - Nasdaq
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):